More than 80% of HHT patients have mutations in endoglin (ENG, HHT1) or activin receptor-like kinase 1 (ALK1 also known as ACVRL1, HHT2) genes [4]. This evidence concerns the gene ENG and hereditary hemorrhagic telangiectasia.